Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Definitions

• Vamorolone is a synthetic glucocorticoid corticosteroid, also known as VB-15, VBP-15, 16 ⁇ -methyl-9, 11 -dehydroprednisolone, or 17 ⁇ ,21-dihydroxy-16 ⁇ -methylpregna- 1,4,9(11)-triene-3,20-dione:
• Vamorolone is an anti-inflammatory drug feat potently binds to the glucocorticoid receptor and has anti-inflammatory effects similar to traditional glucocorticoid drugs such as prednisone and defl azacort Vamorolone differs, however, from all 33 drugs in the corticosteroid class by lacking an 11-carbon oxygen group (hydroxyl or carbonyl) that is 1 of 5 molecular contact sites with the glucocorticoid receptor In-vitro pharmacology and pre- ciinical in vivo studies have shown that vamorolone retains the anti-inflammatory activity of steroid drugs while lacking the adverse effects (AEs) for these drugs, including stunting of growth, bone morbidities, and muscle atrophy, in these models.
• AEs adverse effects
• vamorolone is a potent antagonist of the mineralocorticoid receptor, similar in activity to eplerenone and spironolactone
• the differential mechanism of action of vamorolone compared to traditional corticosteroid anti-inflammatory drugs is attributed to the loss of gene transcriptional activities for glucocorticoid response element-binding and activation, potent antagonist activity for the mineralocorticoid receptor superior membrane stabilization properties, and retention of the distinct NF- ⁇ B inhibitory (anti-inflammatory) activities.
• NF- ⁇ B activation leads to skeletal muscle loss; proinflammaiory cytokines, tumor- derived factors, and other mediators of muscle atrophy function through activating NF- ⁇ B.
• Activation of NF- ⁇ B-related ceil damage pathways is recognized as one of the earliest molecular pathologies of dystrophin-deficient muscle in Duchenne muscular dystrophy (DMD) patients. Inhibition of NF- ⁇ B activity can prevent skeletal muscle loss in patients with DMD and other diseases.
• deceleration of linear growth commonly referred to as “growth stunting” — is a consequence of chronic corticosteroid treatment. Accordingly, there remains a need in the art for treatments for NF- ⁇ B-rnediated diseases in humans, particularly treatments that will be administered chronically and do not stunt growth.
• kits for treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, without increasing the incidence of vertebral fractures in the human patient comprising administering to the human patient in need thereof a therapeutically effective amount of a compound having the structural formula
• a method of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old. without decreasing lean body composition and bone density in the human patent comprising administering to the human patient in need thereof a therapeutically effective amount of a compound having the structural formula
• a method of treating or reducing the symptoms of muscular dystrophy in a human pad ent between the age of 1 day and 18 years old, wherein the human patient demonstrates reduced positive transcriptional activity comprising administering to the human patient in need thereof a therapeutically effective amount of a compound having the structural formula
• Figure I shows a flow diagram for the manufacturing process used to make the aqueous oral pharmaceutical suspension composition comprising vamorolone Form I described in Example 3.
• Figure 2 shows a flow diagram for the manufacturing process used to make the aqueous oral pharmaceutical suspension composition comprising vamorolone Form I described in Example 4.
• FIG. 3 shows participant-level longitudinal data (change from baseline after an 18-month treatment period) comparing vamorolone-associated efficacy to Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) external comparators.
• Vamorolone group A was treated with 2.0 or 6.0 mg/kg/day for the last 3-9 months of the 18 months
• group B was treated with 2.0 or 6.0 mg/kg/day for foe last 9—11 months
• groups C and D with 2,0 or 6.0 mg/kg/day for all 18 monfcs.
• FIG. 4 shows mean group cross-sectional data comparing vamorolone- associated efficacy to CINRG DNHS external comparators (analysis at age 5.5-8.5 years) Vamorolone group A was treated with 2.0 or 6.0 mg/kg/day for the last 3-9 months of the 18 months (blue circles), group B was treated with 2.0 or 6.0 mg/kg/day for the last 9- 11 months (red squares), and groups C (green triangles) and D (purple triangles) with 2.0 or 6.0 mg/kg/day for ail 18 months Ihe baseline mean is shown for each vamorol one-treated group (black line).
• corti c-osteroid-treated natural history group (n ::: 68) has no baseline shown, as the age at initiation of corticosteroids was variable.
• This panel shows improvement over baseline in vamorol one-treated groups B, C, and D.
• the cross-sectiona.1 data suggest an effect size similar to that of age-group-matched corticosteroid treated participants in CINRG DNHS.
• Figure 5 shows the Statnre-for-age and Weight-for-age percentiles in boys aged 2 to 20 years, developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000), available at www. cd c. go v/growthcharts .
• Figure 6 shows BMI z-score comparison of vamorolone LTE vs. CINRG DNHS cohorts with individual trajectories.
• Figure 7 shows foe height percentile comparison of vamorolone LTE vs. CINRG DNHS cohorts with individual trajectories.
• vamoroione refers to 17 ⁇ ,21 -dihydroxy -16u-methyipregua- 1.4,9(11 )-triene-3, 20-dione (also known as VBP15 or VB-15) and has the structure:
• Vamorolone can exist as various polymorphic forms.
• polymorphs and “polymorphic forms” and related terms herein refer to crystalline forms of the same molecule. Different polymorphs may have different physical properties such as, for example, melting temperatures, heats of fusion, solubilities, dissolution rates, and/or vibrational spectra because of the arrangement or conformation of the molecules in the crystal lattice. The differences in physical properties exhibited by polymorphs affect pharmaceutical parameters such as storage stability, compressibility' and density (important m formulation and product manufacturing), and dissolution rates (an important factor in bioavailability).
• Differences in stability can also result from changes in chemical reactivity (e.g., differential oxidation, such that a dosage form discolors more rapidly when comprised of one polymorph than when comprised of another polymorph) or mechanical property (e.g., tablets crumble on storage as a kinetically favored polymorph converts to thermodynamically more stable polymorph) or both (e.g., tablets of one polymorph are more susceptible to breakdown at high humidity').
• chemical reactivity e.g., differential oxidation, such that a dosage form discolors more rapidly when comprised of one polymorph than when comprised of another polymorph
• mechanical property e.g., tablets crumble on storage as a kinetically favored polymorph converts to thermodynamically more stable polymorph
• both e.g., tablets of one polymorph are more susceptible to breakdown at high humidity'
• Polymorphs of a molecule can be obtained by several methods, as known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, desolvation, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, and sublimation
• Techniques for characterizing polymorphs include, but are not limited to. differential scanning calorimetry (DSC), X-ray powder diffractometry (XR.PD), single-crystal X-ray diffractometry, vibrational spectroscopy, e.g., IR and Raman spectroscopy, solid-state NMR, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility studies, and dissolution studies.
• DSC differential scanning calorimetry
• XR.PD X-ray powder diffractometry
• XR.PD single-crystal X-ray diffractometry
• vibrational spectroscopy e.g., IR and Raman spectroscopy
• solid-state NMR solid-state NMR
• SEM scanning electron microscopy
• PSA particle size analysis
• surface area analysis solubility studies, and dissolution studies.
• Form X patern shows a peak at an angle where no peaks appear in the Form ⁇ or Material N pattern, then tha t peak, for that compound, distinguishes Form X from Form ⁇ and Materi al N and further acts to characterize Form X.
• the collection of peaks that distinguish, e.g.. Form X from the other known forms, may be used to characterize Form X.
• Those of ordinary sksli in the art will recognize that there are often multiple ways to characterize solid forms, including using the same analytical technique Additional peaks could also be used, but are unnecessary’, to characterize the form up to include an entire diffraction pattern. Although all the peaks within an entire XRPD pattern may be used to characterize such a form, a subset of that data may. and Apically is, be used to characterize the form.
• An XRPD pattern is an x-y graph with a diffraction angle (typically “29) on the x- axis and intensity on die y -axis.
• the peaks within this pattern may be used to characterize a crystalline sohd form.
• the data are often represented solely by the diffraction angle of the peaks rather than including the intensity of the peaks because peak intensity can be particularly sensitive to sample preparation (for example, particle size, moisture cement, solvent content, and preferred orientation effects influence the sensitivity), so samples of the same material prepared under different conditions mat’ yield slightly different patterns; this variability is usually greater than the variability in diffraction angles. Diffraction angle variability may also be sensitive to sample preparation.
• the term “about” is intended to qualify the numerical values it modifies, denoting such a value as a variable within a margin of error When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well taking into account significant figures.
• administering means to provide a compound or other therapy, remedy, or treatment such tliat an individual internalizes a compound.
• the term “disease” is intended to be generally synonymous, and is used interchangeably with, the terms “disorder” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
• “in need of treatment” and “in need thereof’ when referring to treatment are used interchangeably to mean a judgment made by a caregiver (e.g., physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the ease of animals, including non-human mammals) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors in the realm of a caregiver’s expertise, but that includes the knowledge that the individual or animal is ill, or wifi become ill. as the result of a disease, condition, or disorder that is treatable by the compounds of the invention. Accordingly, the compounds of the invention can be used in a protective or preventive manner; or compounds of the invention can be used to alleviate, inhibit or ameliorate the disease, condition, or disorder.
• NF-kB-mediated disease refers to a disease having a significant and pathologic inflammatory component that can be addressed by inhibition of NF- ⁇ B.
• dfite disease may be completely or partially mediated by modulating the activity or amount of NF- ⁇ B.
• the disease is one in which modulation of NF- ⁇ B results in some effect on the underlying disease, e.g. , administration of a NF- ⁇ B modulator results in some improvement in at least some of the patients being treated.
• NF- ⁇ B-mediated disease also refers to the following diseases, even though the compounds disclosed herein exert their effects through biological pathways and/or processes other than NF- ⁇ B: muscular dystrophy, arthritis, traumatic brain injury, spinal cord injury, sepsis, rheumatic disease, cancer atherosclerosis, type 1 diabetes, type 2 diabetes, leptospiriosis renal disease, glaucoma, retinal disease, ageing, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, ischemia/reperfusion, stroke, cerebral aneurysm, angina pectori s, pulmonary disease, cystic fibrosis, acid-induced lung injury', pulmonary' hypertension, asthma, chronic obstructive pulmonary disease, Sjogren’s syndrome, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, gut diseases, peritoneal endometriosis
• pharmaceutical composition means a composition comprising at least one active ingredient, such as vamorolone or a polymorphic form thereof, whereby foe composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
• active ingredient such as vamorolone or a polymorphic form thereof
• foe composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
• the term “pure” means about 90-100%, preferably 95-100%, more preferably 98-100% (wt/wt) or 99-100% (wt/wt) pure compound; e.g., less than about 10%, less than about 5%, less than about 2% or less than about 1% impurity is present.
• impurities include, e.g., degradation products, oxidized products, epimers, solvents, and/or other undesirable impurities.
• room temperature refers to a temperature of 68 to 86 F.
• stable refers to both chemical (shelf-life) and physical stability (suspension uniformity). Improved uniformity results in an improved product because less shaking of the suspension is required before dosing and allows the product to be stored longer (i.e., longer shelf-life) because the drug in the product will not settle and compact.
• suspension refers to a mixture of a solid in a liquid
• emulsion refers to a mixture of two immiscible liquids.
• the term “therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio and are effective for their intended use
• the phrase “therapeutically effective” is intended to qualify the amount of active ingredients used to treat a disease or disorder This amount will achieve the goal of reducing or eliminating the disease or disorder.
• treating means ameliorating a disease to reduce or eliminate its cause, its progression, its severity, or one or more of its symptoms, or otherwise beneficially alter the disease in a subject.
• prevention means complete protection from disease, such as in the case of prevemion of infection with a pathogen, or may involve prevention of disease progression, for example, from prediabetes to diabetes.
• prevention of a disease may not mean complete foreclosure of any effect related to the disease at any level, instead, it may mean preventing the symptoms of a disease to a clinically significant or detectable level.
• Prevention of diseases may also mean prevention of the progression of a disease to a later stage of the disease. Prevention may be preemptive; i.e , it may include prophylaxis of disease in a subject exposed to or at risk for the disease.
• stunting of growth means a negative change in height percentile for age for a human patient Stunting of growth is measured against age-normalized population-based normative curves m children (for example, see Figure 5 and other clinical growth charts, based on age and sex) and quantified as percentiles against the population means. Stunting of growth may also be referred to as having or showing growth deceleration (e.g., linear growth deceleration). In contrast, a human patient not having or showing stunting of growth may be described as maintaining growth velocity or trajectory.
• a "dose” means the measured quantity of an active agent to be taken al one time by a patient.
• a "dosage” is the prescribed administration of a specific amoum, number, and frequency of doses over a specific period of time.
• risk means the probability or chance of adverse reaction, injury, or other undesirable outcome arising from a medical treatment.
• An "acceptable risk” means measuring the risk of harm, injury, or disease arising from a medical treatment that an individual or group will tolerate. Whether a risk is “acceptable” will depend upon the advantages that the individual or group perceives to be obtainable in return for taking the risk, whether they accept whatever scientific and other advice is offered about the magnitude of the risk, and numerous other factors, both political and social.
• An "acceptable risk” of an adverse reaction means that an individual or a group in society is willing to take or be subjected to the risk that the adverse reaction might occur since the adverse reaction is one whose probability of occurrence is small or whose consequences are so slight, or the benefits (perceived or real) of the active agent are so great.
• An “unacceptable risk” of an adverse reaction means that an individual or a group in society is unwilling to take or be subjected to the risk that the adverse reaction might occur upon weighing the probability of occurrence of the adverse reaction, the consequences of the adverse reaction, and the benefits (perceived or real) of the active agent.
• “At-risk” means in a state or condition marked by a high level of risk or susceptibility Risk assessment consists of identifying and characterizing title nature, frequency, and seventy of the risks associated with t-smg a product.
• safety means the incidence or severity of adverse events associated with administration of an active agent, including adverse effects associated with patient-related factors (e.g.. age. gender, ethnicity, race, target illness. abnormalities of renal or hepatic function, co-morbid illnesses, genetic characteristics such as metabolic status, or environment) and active agent-related factors (e.g., dose, plasma level, duration of exposure, or concomitant medication).
• patient-related factors e.g.. age. gender, ethnicity, race, target illness. abnormalities of renal or hepatic function, co-morbid illnesses, genetic characteristics such as metabolic status, or environment
• active agent-related factors e.g., dose, plasma level, duration of exposure, or concomitant medication
• dowm-titration or "'dose de-escalation” of a compound refers to decrease the amount of a compound to achieve a therapeutic effect that occurs before administration of the compound is terminated. Down-titration can be achieved in one or more dose increments, which may be the same or different
• up-titration refers to increasing the amount of a compound to achieve a therapeutic effect that occurs before dose- limiting intolerability' for the patient. Up-titration can be achieved in one or more dose increments, which may be the same or different.
• maximum recommended total daily dose or “maximum recommended daily dosage” or ‘"maximum total daily dose” or 'maximum daily dosage” or ' ‘total daily dosage” refers to the highest safe dosage of drug to be administered on a daily basis following dosage titration, i.e., the maintenance dose, as determined by a titration scheme, should not exceed the maximum recommended total daily dose.
• a method of treating or reducing the symptoms of an NF- ⁇ B-mediated disease in a human patient between the ages of 1 day and 18 years old, without stunting the human patient’s growth comprising administering to the human patient in need thereof a therapeutically effective amount of a compound having the structural formula or a salt or polymorph thereof.
• Also provided is a method of treating or reducing the symptoms of Duchenne muscular dystrophy in a human patient comprising administering to the human patient in need thereof a therapeutically effective amount of a compound having the structural formula or a salt or polymorph thereof, thereby resulting in the treatment or prevention of one or more signs or symptoms of Duchenne muscular dystrophy
• the signs or symptoms of Duchenne muscular dystrophy comprise one or more of progressive proximal weaimess with onset in the legs and pelvis. hyperlordosis with wide-based gait, hypertrophy of weak muscles, pseudohypertrophy (enlargement of calf and deltoid muscles with fat and fibrotic iissue). reduced muscle contractility on electrical stimulation in advanced stages of the disease, delayed motor milestones, progressive inability to ambulate, heel cord contractures, paralysis, fatigue, skeletal deformities including scoliosis, muscle fiber deformities, cardiomyopathy, congestive heart failure or arrhythmia, muscular atrophy, and respiratory disorders,
• the NF-kB-mediated disease is one that is commonly treated with chronic administration of a corticosteroid
• the corticosteroid binds the glucocorticoid receptor and is an antagonist of the mineralocorticoid receptor
• the treatment is characterized by fewer corticosteroid- associated safety concerns than a human patient treated with deflazacort, prednisone, or prednisolone
• the one or more adverse events is chosen from
• the corticosteroid-associated safety concern is chosen from bone fragility and fracture (e.g., spinal fracture), reduced or delayed growth (stunting of growth), hypogonadism, weight gain, behavioral effects (e.g., mood disturbance, irritability, or personality change), diabetes, hypertension, Cushingoid appearance, sleep disorder, hirsutism, and increased appetite.
• bone fragility and fracture e.g., spinal fracture
• reduced or delayed growth e.g., reduced or delayed growth (stunting of growth)
• hypogonadism e.g., weight gain
• behavioral effects e.g., mood disturbance, irritability, or personality change
• diabetes e.g., hypertension, Cushingoid appearance, sleep disorder, hirsutism, and increased appetite.
• growth is measured by change in mean height percentile for age
• the human patient has a positive growth trajectory.
• the human patient has an increase in height percentile of at least 6.
• the NF- ⁇ B-mediated disease is a chrome disease.
• the chronic disease is an inflammatory disease.
• the chronic disease is a muscle-wasting disease.
• the muscle-wasting disease is a muscular dystrophy.
• the muscular dystrophy is chosen from Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery -Drei fuss muscular dystrophy.
• the muscular dystrophy is chosen from Duchenne muscular dystropliy and Becker muscular dystropliy. In some embodiments, the muscular dystropliy is Duchenne muscular dystrophy. In some embodiments, the muscular dystrophy is Becker muscular dystrophy.
• administration is for at least 6 months. In some embodiments, administration is for at least 12 months. In some embodiments, administration is for at least 18 months. In some embodiments, administration is for at least 24 months. In some embodiments, the administration is for at least 30 months.
• the months are consecutive.
• the months are cumulative.
• between about 1 mg/kg/day and about 12 mg/kg/day of the compound is administered.
• between about 2 mg/kg/day and about 6 mg/kg/day of the compound is administered.
• the vamorolone, or a salt or polymorph thereof is administered via a titration scheme
• the goal of the titration scheme is to achieve an optimal level of disease control in which the patient is tolerating the treatment regimen, or has achieved satisfactory treatment, or. in the ease of up-titration, until the maximum permitted dose is reached, or, in the case of down-titration, until administration of the vamorolone, or a salt or polymorph thereof, is terminated.
• the vamorolone, or a salt or polymorph thereof is administered via a titration scheme that comprises the down-titration of the vamorolone, or a salt or polymorph thereof, until a maintenance dose is administered.
• the down-titration scheme comprises: administering rar im dal dose of the vamorolone. or a salt or polymorph thereof monitoring the reduction of symptoms of the NF-kB-mediated disease and tolerability' of the patient to the treatment, administering a reduced dose of the vamorolone, or a salt or polymorph thereof [0080] In some embodiments, the cycle of monitoring and reducing the dose that is administered is repeated until a maintenance dose is administered.
• the initial dose in a down-titration scheme is about 6 mg/kg/day. In some embodiments, the initial dose is about 5 mg/kg/day In some embodiments, the initial dose is about 4 mg/kg/day. In some embodiments, the initial dose is about 3 mg/kg/day.
• the dose is reduced by an increment of about 0..5, about 1.0, about 1 5, about 25, about 3, about 3.5, or about 4 mg/kg/day.
• the increment is about 0..5 mg/kg/day.
• she increment is about 1 mg/kg/day.
• the increment is about 1 .5 mg/kg/day.
• the increment is about 2 mg/kg/day.
• title increment is about 2.5 mg/kg/day.
• the increment is about 3 mg/kg/day .
• the increment is about 3.5mg/kg/day.
• the increment is about 4 mg/kg/day.
• the initial dose is about 6 mg/kg/day and the reduced dose is about 2 mg/kg/day.
• the vamorolone, or a sail or polymorph thereof is administered via a titration scheme that comprises the up-titration of the vamorolone, or a salt or polymorph thereof until a maintenance dose is administered.
• the up-titration scheme comprises: administering an initial dose of the vamorolone, or a salt or polymorph thereof, monitoring the reduction of symptoms of the NF-kB-mediated disease and tolerability of the patient to the treatment, administering an increased dose of the vamorolone, or a salt or polymorph thereof [0086] In some embodiments, the cycle of monitoring arid increasing the dose that is administered is repeated until a maintenance dose is administered
• the initial dose for the up-titration scheme is about 2 mg/kg/day. In some embodiments, the initial dose is about 2.5 mg/kg/day. In some embodiments, the initial dose is about 3mg/kg/day. In some embodiments, the initial dose is about 3.5 mg/kg/day.
• the dose is increased by an increment of about 0..5. about 1 , about 1.5, about 2, about 2.5, about 3. about 3.5, or about 4 mg/kg/day
• the increment is about 0..5 mg/kg/day.
• the increment is about 1 .0 mg/kg/day.
• the increment is about 1 5 mg/kg/day.
• the increment is about 2 mg/kg/day.
• the increment is about 2.5 mg/kg/day.
• the increment is about 3 mg/kg/day.
• the increment is about 3.5 mg/kg/day.
• die increment is about 4 mg/kg/day.
• the initial dose is about 2 mg/kg/day and the increased dose is about 6 mg/kg/day.
• the maintenance dose is about 6 mg/kg/day. In some embodiments, the maintenance dose is about 5.5 mg/kg/day. In some embodiments, the maintenance dose is about 5 mg/kg/day. In some embodiments, the maintenance dose is about 4.5 mg/kg/day. In some embodiments, the maintenance dose is about 4 mg/kg/day. In some embodiments, the maintenance dose is about 3.5 mg/kg/day. in some embodiments, the maintenance dose is about 3 mg/kg/day. In some embodiments, the maintenance dose is about 2.5 mg/kg/day. In some embodiments. the maintenance dose is about 2 mg/kg/day. In some embodiments, the maintenance dose is about 1 5 mg/kg/day In some embodiments, the maintenance dose is about 1 mg/kg/day.
• the human patient is a child.
• the human patient is between 2 and 18 years old
• the human patient is between 4 and 12 years old.
• the human patient is between 4 and 7 years old.
• the Duchenne muscular dystrophy is typically diagnosed in young children but can be, and lias been, diagnosed in utero by gene test and confirmatory fetal muscle biopsy Accordingly, patients may be treated as soon abler birth as a physician deems appropriate.
• the human patient is male.
• the human patient is female.
• the compound is administered orally.
• the compound is administered as a solution or suspension.
• the solution or suspension comprises about 4 wt.% of the compound.
• the solution or suspension further comprises a flavoring agent
• the treatment is characterized by an increased velocity for time run/walk ten meters (ITRW).
• the TTRW velocity increased by at least 0.3 meters per second (e g.., 0..3 to 1 meters per second).
• the treatment is characterized by an increased velocity for time to climb four stairs (TTCLIMB).
• the TTCLIMB velocity increased by at least 0.05 stairs per second (e.g , 0..05 to 1 5 stairs per second)
• DMD Duchenne's muscular dystrophy
• Signs and symptoms of Duchenne's muscular dystrophy include, but are not limited to, frequent falls, difficulty rising from a lying or sitting position, trouble running and jumping, waddling gait, walking on the toes, large calf muscles, muscle pain, and stiffness, learning disabilities, delayed growth.
• Other symptoms are related to treating DMD with corticosteroids, which is the current standard of care.
• the symptom may be an adverse event of special interest (AESI).
• AESIs are prespecified based on pre-defined MedDRA search criteria for eleven AESI categories for the conicosteroid class and then further stratified into AESI of at least moderate severity.
• the symptoms for treating DMD with corticosteroids include, but is not limited to, behavior adverse events, blood glucose related problems, gastrointestinal symptoms, increased arterial blood pressure, immune suppression/infections, skin/hair changes, cataracts/glaucoma. Cushingoid features, weight gain, bone fractures, slow growth.
• the behavior adverse event is chosen from abnormal behavior, aggression, agitation, anger, anxiety, emotional disorder, irritability, altered mood, mood swings, sleep disorder, initial insomnia, personality change, poor sleep quality, psychomotor hyperactivity, and skin laceration.
• the behavior adverse event is chosen from one or more of aggression, agitation, anger, emotional disorder, irritability, mood swings, sleep disorder, initial insomma, and personality change.
• the behavior adverse event is chosen from one or more of anger, mood swings, and personality change.
• the patient is assessed with a Pediatric Anxiety Rating Scale (PARS) III questionnaire.
• the PARS is a dimensional measure of treatment efficacy
• the PARS is a clinician-rated measure of symptom severity and associated impairment that targets generalized anxiety disorder (GAD), social phobia (SoP), and separation anxiety disorder (SAD)
• GAD generalized anxiety disorder
• SAD separation anxiety disorder
• the PARS consists of a checklist of 50 anxiety symptoms (encompassing SAD, SoP, and GAD) and seven global items administered to the child and parent together. Global items are each rated on a six-point (0-5) scale and reflect the number of symptoms present, their frequency, the severity of anxiety feelings, the severity' of physical symptoms of anxiety, overall avoidance of anxiety -provoking situations, and anxiety -related interference with functioning at and outside of the home.
• the PARS has acceptable psychometric properties and is sensitive to cognitive behavioral therapy (CBT) and pharmacological treatment changes.
• CBT cognitive behavioral therapy
• the comprehensiveness of the PARS is appealing in light of symptom overlap and high rates of comorbidity across anxiety disorders
• the PARS is time-efficient, taking approximately 20-30 minutes to complete.
• the PARS is feasible for routine clinical cars like other interview-based rating scales for assessing severity and treatment response, such as the Children’s Depression Rating Scale Revised and the Children’s Yale-Brown Obsessive Compulsive Scale (CY- BOCS).
• Treatment response is an improvement of sufficient magnitude such tlia.t the individual is no longer fully symptomatic but may continue to evince more than minimal symptoms
• Treatment response is often operationalized as a significant reduction in symptom seventy and/or functional impairment.
• “Remission’” is the absence or near absence of symptoms after treatment, such as treating childhood disorders impacted by residual symptoms during development. Relative to treatment response, remission is a more conservative standard. Remission has been operationalized using binary measures of diagnostic status or dichotomized ratings on dimensional measures of global functioning, which correspond to youth being '"disorder free.” Both treatment response and remission are defined a priori and measured using multiple sources of information
• T'he present disclosure also provides a method of treating or reducing the symptoms of muscular dystrophy 7 in a human patient between the age of 1 day 7 and 18 years old. without decreasing lean body composition and bone density in the human patent, comprising administering to the human patient in need thereof a therapeutically 7 effective amount of a compound having the structural formula
• the body composition and bone density are measured via dual-energy X-ray absorptiometry (DXA).
• DXA measures bone mineral density (BMD) using spectral imaging. Two X-ray beams with different energy' levels are aimed at the patient’s bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone.
• the human patient’s body composition is leaner than in the human patient taking a therapeutically effective amount of prednisone or deflazacort tor treating muscular dystrophy
• the human patient’s bone density 7 is greater than in the human patient taking a therapeutically effective amount of prednisone or deflazacort for treating muscular dystrophy.
• the positive change in bone density is at least 1%, such as at least 5% or at least 10%.
• the human patient’s body composition is leaner, and the bone density is greater than in the human patient taking a therapeutically effective amount of prednisone or deflazacort for treating muscular dystrophy.
• the total body lean mass index of the human patient showed greater positive changes in the human patient who has taken a therapeutically effective amount of prednisone for treating muscular dystrophy.
• Lean body mass (LBM) sometimes conflated with fat-free mass, is a component of body composition.
• Fat-free mass (FFM) is calculated by subtracting body fat weight from total body weight: total body weight is lean plus fat.
• LBM can be measured by DXAand estimated mathematically, such as with the Boer or Hume formulas and other methods available to a person of skill in the art
• the positive changes to LBM are quantified by comparing the LBM of the human patient treated with vamorolone to a similar' human patient taking prednisone.
• the positive change in total body lean mass index is a.t least 1%, such as at least 5% or a.t least 10%.
• foe rate of osteoporosis in foe human patient is less than in the human patient taking a therapeutically effective amount of prednisone or deflazacort for muscular dystrophy.
• EmflazaTM showed higher frequencies of growth delay, Cushingoid appearance, and cataracts than prednisone.
• Other approved treatments for DMD (viltolarsen, etiplersen, golodirsen, casimersen) are mutation-specific, targeting small subpopulations of DMD patients, and are used as an add-on to corticosteroids. These are not considered available therapies as they were granted accelerated approval based on a surrogate endpoint.
• a child's bone age (also called the skeletal age) is assigned by determining which of the standard X-ray images in the atlas most closely match the appearance of the child's bones on the X-ray.
• a difference between a child's bone age and chronological age might indicate a growth problem. The larger the difference between the bone age of a human patient and their chronological age, the greater the growth problem or disease symptom When tins difference between the chronological age and bone age is reduced, the seventy of the growth problem or disease symptom is also reduced.
• the present disclosure further provides a method of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old. wherein the human patient demonstrates reduced positive transcriptional activity, comprising administering to the human patient m need thereof a therapeutically effective amount of a compound having the structural formula
• “Positive transcriptional activity” refers to binding a specific protein (activator) for transcription to begin. DNA-bound activators can regulate transcription by helping with ignition. To do this, they sometimes tether RNA polymerase to the promoter When positive transcriptional activity is reduced, as, in the disclosed methods, the binding of the specific protein is showed or inhibited, thus slowing or delaying die start of transcription.
• the redaction in positive transitional activity is by at least 1%, such as at leasi 5% or at least 10%
• the administration is for at least 6 months In certain embodiments, administering 2 mg/kg/day of the compound has a decreased risk of weight gain for the human patient. In certain embodiments, about 6 mg/kg/day of the compound is administered.
• a 20% aqueous solution of sodium bisulfite (920 mL, 10 vol) was added carefully via an addition funnel, keeping the temperature below 10 °C.
• Trifluoroacetic acid (16 mL, 202 mmol, 1 eq) was added, and foe mixture was held for 3 h at 0-5 °C to complete desilylation (endpoint by HPLC).
• the lower aqueous layer was drained, and the organic layer was washed with a saturated solution of sodium bicarbonate (3 x 250 mL), followed by water (1 x 250 mL) and brine (1 x 150 mL).
• An oral pharmaceutical composition was prepared as a suspension by blending the ingredients in the amounts listed below in 'Table 1 to form a suspension.
• Figure 1 shows a flow diagram for the inamifacturing process used to prepare this suspension.
• FIG. 1 shows a flow diagram for the manufacturing process used to prepare this suspension.
• Another oral pharmaceutical composition was prepared as a suspension by blending the ingredients in the amounts listed below in Table 3 to form a suspension.
• Vamorolone clinical studies have been conducted in adult male volunteers and boys with DMD, a disorder in which skeletal muscle is in a chrome inflammatory state.
• Two consecutive open-label dose-ranging studies in 48 DMD patients aged 4 to ⁇ 7 years (corticosteroid-naive) were conducted (Phase IIa, VBP15-002: Phase Ila, VBP15-003). Doses were tested over a 24-fold dose range (0..25, 0..75, 2.0, and 6.0 mg/kg/day), with 12 participants per group.
• MAD multiple ascending dose
• PK pharmacokinetics
• VBP15-002 2-week washout
• Vamorolone treatment showed no dose-limiting toxi cities.
• PK demonstrated a short half-life similar to corticosteroids ( 2 hours), no drug accumulation, similar PK on day 1 and day 14 PK similar to that of healthy adult male volunteers ( VBP15-001 ).
• All DMD participants completed the MAD study and then continued on the same dose for a 24-week dose-finding (efficacy and safety) extension study (VBP15-003).
• Oral administration of vamorolone at all doses tested was safe and well-tolerated over the 24-week treatment period. Participants in the 2 higher dose groups ( 2.0 arid 6.0 mg/kg/day) generally showed clinical improvement of motor outcomes, suggesting dose-related improvements in all motor outcomes tested
• VBP15-003 After completing the 24-week dose-finding study (VBP15-003), participants had the opportunity to enroll in a 24 -month long-term extension study (VBP15 -LTE) that permitted dose escalations and de-escalations. Ail trial participants’ parents and physicians requested continued access to vamorolone rather than transition to the standard of care (prednisone or deflazacort). The initial experience from the 24-week VBP15-003 trial and the first 12 months of the 24-month VBP15-LTE trial (total 18 months of treatment) are reported below.
• VBP15-002 [NCT02760264]; VBP15 -003 [NCT02760277]; VBP15-LTE [NCT03038399]
• a total of 48 participants were initially enrolled into VBP) 5-002, with trial participants completing month 12 of the 24-month VBP15-LTE study.
• VBP15-002 Phase Ila; two weeks on the drug, two weeks off drug
• VBP15-LTE Forty-six of 48 participants completed the VBP15-003 study (2 participants withdrew from VBP15-003 for reasons unrelated to the study drug). In addition, all participants (46/46) opted to enroll in the 24-month long-term extension study. VBP15-LTE.
• Age-matched CINRG DNHS participants included those continuously corticosteroid-naive over an 18-month period (n :::19) or continuously corticosteroid-treated over an 18-month period (n ::: 68).
• corticosteroid doses and regimens varied based on clinician discretion. Although all 68 participants were treated for 18 months continuously, the age at initiation of corticosteroids varied. Thus, the total duration of corticosteroid treatment was longer than 18 months for most participants.
• VBP15-LTE 24-month long-term extension
• VBP15-lTE protocol permitted multiple-dose escalations to the highest dose (6.0 mg/kg/day) at the participant’s family and physician’s discretion and permitted de- escalations
• Site investigators were permitted to escalate a participant’s dose to a higher dose level during the VBP15-LTE (6.0 mg/kg/day) once the participant had been on their initial dose in VBP) 5-LTE for at least one month, the next higher dose was determined to be safe in the VBP15-002 Phase Ila Study, and no safety- issues with that dose had emerged in the VBP15-003 Phase Ila study
• Vamorolone-treated participants were initially enrolled into VBP15-002 and VBP15-003 in 4 dose groups (0..25, 0..75, 2.0, and 6.0 mg/kg/day: groups A-D).
• vamorolone group A participants Upon entering VBP15-LTE, vamorolone group A participants had 2 or 3 sequential dose escalations and were treated with 2.0 or 6.0 mg/kg/day for the last 3-9 months of the 18 months, group B participants had 1 or 2 dose escalations and were treated with 2.0 or 6 0 mg/kg/day for the last 9-11 months.
• Groups C and D were treated for 18 months at 2.0 or 6.0 mg/kg/day (S 1 Fig).
• the current study is the first to evaluate the longer-term tolerability, efficacy, and safety of vamorolone in DMD.
• the VBP15-003 dose-finding study suggested that vamorolone doses of 2.0 and 6.0 mg/kg/day showed better efficacy and similar safety profiles than lower doses.
• VBP15-LTE iSAP S1 iSAP
• the VBP15-LTE iSAP prespecified analyses of the VBP15-LTE midpoint (12-month) assessments and comparisons to external comparators (corticosteroid -treated and corticosteroid-naive participants from CINRG DNHS).
• the VBP15-LTE iSAP included all month 12 assessments of fee 24-monfe VBP15-LTE study.
• Tire software used was SAS.
• the statistical analyses were carried out in 2 sequential steps. First, groups and comparisons in the VBP15-LTE iSAP were prespecified.
• This iSAP included only those vamorolone-treated participants who had been on 2.0 or 6.0 mg/kg/day for the full 18-month treatment period (dose groups C + D) to avoid the confounding variable of multiple-dose escalations in dose groups A and B (S1 Fig).
• the second analysis was conducted post hoc after completion of the VBP15-LTE iSAP analyses, with dose stratification based on initial dose group in VBP15-002 (0..25 [group A], 0..75 [group B], 2.0 [group Cj, and 6.0 [group D] mg/kg/day).
• Velocity measures are variance-stabilizing transformations, suppressing extreme raw outliers from raw values in seconds; these help with distributional assumptions of the statistical models/tests used. Raw data (seconds) are also reported. Velocity scores for TTSTAND (event/second), TTRW (meters/second), and TTCL1MB (event/ second) were inputted as 0 at the first response missing due to inability to perform foe test. All other data were observed values only, without imputation. No adjustments for multiplicity on inferential statistics were specified in foe iSAP.
• VBP15-002 Forty-eight HMD participants were enrolled into VBP15-002 and entered into 4 vamorolone treatment groups (dose group A, 0.25 mg/kg/day: dose group B, 0 75 mg/kg/day; dose group C, 2.0 mg/kg/day; dose group D. 6.0 mg/kg/day). All 48 participants completed the 4-week VBP15-002 trial, and 46 completed the 24 ⁇ week VBP15-003 trial at the same doses. All 46 participants completing the 24-week VBP15-003 study then opted to enroll in the 24-month long-term extension study (VBP15-LTE).
• VBP15-LTE 24-month long-term extension study
• the current study is the first to evaluate the longer- term tolerability, efficacy, and safety of vamorolone in DMD
• the VBP15-003 dose-finding study suggested that the two higher vamorolone doses showed greater efficacy than the two lower doses.
• each participant could have his dose of vamorolone increased to a higher dose or decreased to a lower dose by the site investigator as necessitated clinically.
• the vamorolone dose was increased to 2.0 mg/kg/day for 3 participants and 6.0 mg/kg/day for 8 participants before the 12-month interim assessment
• the cumulative exposure to high-dose vamorolone (2.0 or 6.0 mg/kg/day) for those originally in the 0.25- mg/kg/day dose group ranged from 3 to 9 months (of the 18-month study period).
• the vamorolone dose was increased to 2.0 mg/kg/day for 6 participants and to 6.0 mg/kg/day for 6 participants.
• the cumulative exposure to high-dose vamorolone for those originally in the 0.75-mg/kg/day dose group ranged from 9 to 11 months.
• the dose remained at 2.0 mg/kg/day for 3 participants and was increased to 6.0 mg/kg/day for 9 participants.
• AU eleven participants in the 6.0-mg/kg/day /day at entry in the VBP15-UEE remained at this dose throughout the study.
• the 18-month value reflects the outcome at 12 months of treatment, as this was the duration for tire prednisone trial.
• Baseline indicates mean BMI at the beginning of the 18-month continuous treatment with corticosteroids. Participants may have been initiated on corticosteroids before tins visit
• Participant-level data were analyzed graphically for the four vamorolone-treaied groups relative to DNHS corticosteroid-naive participants (Figs 3 and 4) Groups B, C, and D each showed improvements from baseline after 18 months of treatment compared to corticosteroid-naive participants from CINRG DNHS. In contrast, group A outcomes were similar to those of corticosteroid-naive participants. Of note, group A was treated for only 3 to 9 months with high-dose vamorolone and was also had a mean age 0.4 years older than that of the other groups at study entry (Group A, 5.2 ⁇ 1.0 years; Groups B, C, and D, 4.8 ⁇ 0.8 years).
• Vamorolone dose groups B, C, and D showed motor function outcomes similar to those of corticosteroid-treated DNHS participants.
• Corticosteroid-naive participants showed poorer performance, as did vamorolone group A.
• Fig 3 shows the participant-level change from baseline after an 18-month treatment period.
• Vamorolone group A was treated with 2.0 or 6.0 mg/kg/day for the last 3-9 months of foe 18 months
• group B was treated with 2.0 or 6.0 mg/kg/day for foe last 9-11 months
• groups C and D with 2.0 or 6.0 mg/kg/day for all 18 months.
• the vamorolone-treated group had a normal mean BMI at baseline (z-score ::: 1.03).
• Participants in the CINRG prednisone clinical trial showed an increase of mean z-score of 0.46 over 12 months of treatment, and the vamorolone group showed an increase of mean z-score of 041 over 18 months of treatment.
• PODCI is the Pediatrics Outcomes Data Collection instrument (musculoskeletal disorders).
• the PODCI is a disease-specific questionnaire developed by the American Academy of Orthopedic Surgeons to measure general health and problems related to bone and muscle conditions in children.
• a significant increase in mean PODCI upper extremity and physical function standardized score was observed from LIE baseline to Month 24
• TEAEs Treatment-emergent AEs
• VBP15-002 2-week treatment MAD study
• VBP15-003 24-week dose-finding extension study
• TEAEs were reported with similar incidence by participants in ah four vamorolone groups.
• Several TEAEs commonly observed with chronic corticosteroid therapy were observed only in the 2.0 ⁇ mg/kg/day group (abnormal behavior: one participant) and 6.0- mg/kg/day group (hypertrichosis [two participants] and anxiety; abnormal blood cortisol level, Cushingoid habitus, and personality change [one participant each]).
• the other reported TEAEs did not exhibit a dose-related incidence.
• AEs myoglobinuria events [in the same participant] and one pneumonia
• 402 were deemed unrelated to vamorolone
• 37 were deemed remotely related
• 29 were deemed possibly related
• 11 were deemed probably related
• Vamorolone data are from Data Safety Update Report 13 March 2019 (data cutoff 9 January 2019). Data shown are physician-reported adverse events. l Mean age shown for vamorolone is a cross-sectional analysis; the mean age shown for Griggs ei al. is at baseline. z No behavior change was reported, but one personality change, one sleep disorder, and two irritability were reported.
• VBP15-LTE 2-year long-term extension study
• corticosteroid standard of ca.re deflazacort or prednisone
• Vamorolone-treated participants showed improvements from baseline in ali five moior assessments over the 18- month treatment period (TTSTAND, TTRW, TTCLIMB, NSAA, and 6MWT) (Table 5).
• Vamorolone has shown fewer morbidities than corticosteroids in mouse disease models, but a comparative safety profile for vamorolone versus corticosteroids has not been previously reported in humans.
• Group-matched steroid-treated participants in the CINRG DNHS showed marked stunting of growth — a well-known safety concern with chronic deflazacort and prednisone treatment of children. In contrast, vamorolone-treated participants did not show any evidence of stunting of growth.
• DMD patients at this young age range are, on average, stable or improving. To interpret these results, clinical improvements should be compared to the control of non-treated participants.
• the vamorolone clinical trials were conducted by the academic clinical trial network CINRG.
• the CINRG network had previously conducted a longitudinal natural history study of 551 DMD participants and healthy peers (CINRG DNHS), with similar clinical evaluator methods and endpoints used in the vamorolone trials.
• Prespecified matching criteria were defined to provide group matching of corticosteroid-naive and corticosteroid -treated cohorts selected from the CINRG DNHS to compare to vamorolone- treated participants over 18 months.
• the comparator groups were similar to the vamorolone- treated groups at baseline, with slightly older ages in the CINRG DM IS study groups.
• FIG. 1 The cross-sectional graphical compari son of motor outcomes at the end of the 18- month treatment period (participants 5.5-8.5 years of age) is shown in Fig 1. These outcomes suggest both the vamorol one-treated cohort (1 year or more treatmem at 2.0 or 6 0 mg/kg/day: groups B, C. and D) and the CINRG DNHS corticosteroid -treated cohort had similar drug-related benefits relative to the CINRG DNHS corticosteroid-naive cohort.
• vamorolone treatment of DMD patients provides similar efficacy as corticosteroid treatment as assessed by motor function outcomes
• tins preliminary assessment indicates that vamorolone treatment resulted in fervor safety concerns typical for corticosteroid treatment
• the BM1 data from the 18-rnonth extension in comparison to natural history data from the CINRG do not indicate that vamorolone-treated participants will be w holly spared the side effects of weight gam, and two participants on 6 0 mg/kg/day had to de-escala.te their dose to 2.0 mg/kg/day
• vamorolone treatment for 18 months is efficacious compared to a natural history cohort of corticosteroid-naive patients. It appears to be well tolerated, with fewer safety concerns than typically seen with long-term standard-of- care corticosteroid treatment and lacking the stunting of growth that other approved corticosteroids cause. Further studies will directly compare vamorolone to prednisone and are expected to yield results consistent with those presented herein.
• VISION -DMD is a pivotal Phase 2b study (VBP15-004) designed to demonstrate the efficacy and safety of vamorolone compared to placebo and prednisone (active control) for treating DMD.
• VBP15-004 Phase 2b study
• 121 ambulant boys aged 4 to ⁇ 7 years with DMD were randomized to receive vamorolone (low' dose 2 mg/kg/day or high dose 6 mg/kg/day) or prednisone (0.75 mg/kg/day) or placebo.
• the second period of 24 weeks, where all participants receive vamorolone treatment on either of the two dose levels, will continue to capture additional longer-term safety and tolerability data.
• the study met its primaty endpoint of superiority' in the change of time to stand from supine positioning to standing (TTSTAND) velocity with vamorolone 6 mg/kg/day versus placebo (p ::: 0.002) with a treatment difference of 0.06 [95% Cl: 0.02-0.10] rises/second from baseline This result corresponded to a clinically relevant improvement in TISTAND in the vaniorolone 6 mg/kg/day group from 6.0 to 4.6 seconds and a corresponding deterioration in the placebo group from 5.4 to 5.5 seconds.
• the study also demonstrated superiority of vamorolone versus placebo across four of its secondary endpoints, including (in the order of pre-defined hierarchy): TI STAND velocity for
• Vamorolone at both doses of 2 and 6 mg/kg/day showed a favorable safety and tolerability profile.
• no grade 3 or higher treatment-emergent adverse events (TEAEs) or adverse events leading to study discontinuation were observed.
• vamorolone 2.0 mg/kg/day group showed overall stable height change Z scores, but tins did not reach significance relative to the growth deceleration seen with prednisone These 24-week data were consistent with the absence of stunting of growth safety concern of prednisone and deflazacort in Example 3.
• Bone turnover biomarkers showed prednisone to strongly reduce all bone biomarkers (osteocalcin. P1NP, and CTX) at Week 24. In contrast, vamorolone did not decrease bone biomarkers (p ⁇ 0 001 for both vamorolone 2.0 mg/kg and 6.0 mg/kg vs. prednisone for all three biomarkers) (Table 9).
• Pre-specified AESIs typically for corticosteroids were higher in prednisone-treated subjects than vamorolone-treated subjects after 24 weeks of treatment (Table 10). This difference was driven by a higher incidence of behavior problems in prednisone-treated subjects (32.3%) compared to vamorolone- treated subjects (16.7% and 21.4% in the 2.0 and 6.0 mg/kg dose groups, respectively) (Table 11).
• Vamorolone also showed a superior safely profile compared to prednisone for clinically relevant TEAEs, prospectively defined as TEAEs of at least moderate seventy, serious AEs, or TEAEs leading to treatment discontinuation (Table 10). This also reflects the difference between vamorolone and prednisone in behavior-related AEs, with clinically relevant psychiatric events reported by 19.4% of prednisone-treated subjects compared to no vamorolone-treated subjects.
• vamorolone and prednisone emerged after only 24 weeks of treatment, based on trends seen for other AESIs within this short period, it can be expected that additional clinical safety differences may be seen after longer vamorolone treatment periods in this study when compared to the corticosteroid-treaied cohort in the FOR-DMD study.
• PDN prednisone; VAfofovamorolone; TEA. Emreatment-emeigent adverse event;
• AES fo adverse event of special interest n (%) represents number and percentage of subjects reporting one or more events; 6 ⁇ frequency of adverse events (AE count) !
• AESI categories (behavior problems, blood glucose related problems, gastrointestinal symptoms, increased arterial blood pressure, immune suppression / infections, skm/hair changes, cataracts,' 'glaucoma, Cushingoid features, weight gain, bone fractures, slow growth)
• Adverse events of at least moderate seventy, serious adverse events and adverse events leading to discontinuation "Statistically significant difference (p ⁇ 0 05) vs. prednisone in hazard ratio based on proportional means regression models for recurrent events, i e., allowing multiple events for each subject
• PDN prednisone; VAM ⁇ vamorolone: n (%) represents the number and percentage of subjects reporting one or more events; F-frequency of adverse events (AE count) ’Based on a pre-defined search of MedDRA terms, as defined in the statistical analysis plan for study VBP-004 fofrfo In summary; for efficacy, vamorolone was significantly superior compared to placebo on the primary and four of the secondary' outcomes. Bone loss caused by the corticosteroid class can predispose DMD pediatric patients to vertebral and long bone fractures, stunting of growth, bone fragility, and osteopenia. These effects impact the quality of life and may cause discontinuation of corticosteroid treatment with the resulting progression of the disease. Preliminary evidence also suggests that vamorolone has an improved safety profile on behavioral adverse events relative to corticosteroids.
• vamorolone was effective over a three-fold range of doses, between 2 mg/kg/day to 6 mg/kg/day. This range permits physicians to prescribe, for example, an initial dose of 6 mg/kg/day and down titrate to a dose below 6 mg/kg/day and down to 2 mg/kg/day. Safety concerns were also improved compared to corticosteroids. ’Th us. vamorolone fulfills an unmet medical need for treating DMD as it provides statistically significant and clinically meaningful efficacy on motor outcomes vr. placebo with comparable efficacy to prednisone, but without the severe bone morbidities that limit treatment with corticosteroids. Vamorolone will snare DMD boys from bone morbidities and potentially behavioral problems for the corticosteroid class.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)

Priority Applications (10)

Applications Claiming Priority (6)

Related Child Applications (1)

Publications (1)

Family

ID=80776432

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (1)

Citations (3)

Family Cites Families (2)

• 2021
  • 2021-09-21 WO PCT/US2021/051274 patent/WO2022061287A1/en not_active Ceased
  • 2021-09-21 JP JP2023518416A patent/JP2023543439A/ja active Pending
  • 2021-09-21 MX MX2023003258A patent/MX2023003258A/es unknown
  • 2021-09-21 KR KR1020237013258A patent/KR20230092905A/ko active Pending
  • 2021-09-21 IL IL301500A patent/IL301500A/en unknown
  • 2021-09-21 AU AU2021343534A patent/AU2021343534A1/en active Pending
  • 2021-09-21 EP EP21870412.0A patent/EP4213855A4/en active Pending
  • 2021-09-21 CA CA3170698A patent/CA3170698A1/en active Pending
• 2022
  • 2022-02-21 US US17/651,879 patent/US20220184098A1/en not_active Abandoned
• 2023
  • 2023-08-14 US US18/449,312 patent/US20240139210A1/en active Pending

Patent Citations (3)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events